| Nov 18 |
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
|
| Nov 14 |
Allarity Therapeutics GAAP EPS of -$7.71 beats by $0.69
|
| Nov 14 |
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
|
| Oct 22 |
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
|
| Oct 3 |
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
|
| Sep 19 |
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
|
| Sep 17 |
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
Looking Into Allarity Therapeutics's Recent Short Interest
|
| Sep 16 |
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
|
| Sep 13 |
Allarity Therapeutics announces new CFO
|
